Bioventus (NASDAQ:BVS) Announces FY 2026 Earnings Guidance

Key Points

• Bioventus issued FY 2026 adjusted EPS guidance of $0.75-$0.79, broadly in line with the $0.78 analyst consensus, but forecast revenue of $590-$595 million, below the $604.6 million consensus estimate.
• The company’s third-quarter results met expectations, with adjusted EPS of $0.17 and revenue of approximately $142.4 million. However, the reduced revenue outlook points to weaker operating growth, while earnings improvement may be benefiting more from debt paydown than underlying operations.
• Analysts remain broadly positive, with six Buy ratings and a consensus price target of $16.80; shares opened at $13.15 and were trading down 1.3%.

Bioventus (NASDAQ:BVS - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 0.750-0.790 for the period, compared to the consensus estimate of 0.780. The company issued revenue guidance of $590.0 million-$595.0 million, compared to the consensus revenue estimate of $604.6 million.

Bioventus Trading Down 1.3%

Bioventus stock opened at $13.15 on Tuesday. The company has a 50 day moving average price of $13.68 and a 200 day moving average price of $10.90. Bioventus has a 52 week low of $6.47 and a 52 week high of $15.89. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.17 and a current ratio of 1.69. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of 17.08, a P/E/G ratio of 1.87 and a beta of 0.64.

Bioventus (NASDAQ:BVS - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The firm had revenue of $142.44 million for the quarter. Research analysts forecast that Bioventus will post 0.79 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $15.00 price target on shares of Bioventus in a report on Monday, August 17th. Craig Hallum reissued a "buy" rating and issued a $18.00 price objective on shares of Bioventus in a research note on Thursday, August 6th. Barrington Research set a $18.00 price objective on Bioventus in a research report on Thursday, August 6th. Weiss Ratings raised Bioventus from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th. Finally, Canaccord Genuity Group upped their target price on Bioventus from $15.00 to $19.00 and gave the company a "buy" rating in a report on Monday, August 17th. Six investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $16.80.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching the analyst consensus and improving from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS result at or above expectations. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its 2026 adjusted EPS outlook of $0.75 to $0.79, suggesting profitability expectations remain intact even as the revenue outlook was reduced. Bioventus Reaffirms Adjusted EPS Outlook
• Neutral Sentiment: The company reported third-quarter revenue of approximately $142.4 million, along with a 9.36% net margin and 28.08% return on equity. The earnings call transcript provides additional management commentary on the quarter and 2026 outlook. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut its 2026 revenue forecast to $590 million-$595 million after third-quarter sales missed expectations. The revision indicates weaker operating growth and was the primary reason investors reacted negatively to the report. Bioventus Shares Fall on Third-Quarter Sales Miss
• Negative Sentiment: Coverage highlighted that earnings growth is being supported more by debt paydown and related financial benefits than by stronger underlying operations. That raises concerns about the durability of profit growth while revenue momentum remains pressured. Bioventus Cuts Revenue Outlook

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company's offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.